Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,084,019
  • Shares Outstanding, K 59,236
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,020 K
  • EBIT $ -114 M
  • EBITDA $ -114 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.24

Options Overview Details

View History
  • Implied Volatility 119.54% ( -29.21%)
  • Historical Volatility 67.19%
  • IV Percentile 69%
  • IV Rank 48.94%
  • IV High 214.91% on 10/03/25
  • IV Low 28.13% on 09/09/25
  • Put/Call Vol Ratio 45.50
  • Today's Volume 93
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 1.34
  • Today's Open Interest 138
  • Open Int (30-Day) 202

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.43
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.45
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +10.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.80 +4.94%
on 11/07/25
24.64 -28.45%
on 10/31/25
-2.48 (-12.33%)
since 10/07/25
3-Month
16.80 +4.94%
on 11/07/25
24.64 -28.45%
on 10/31/25
-0.27 (-1.51%)
since 08/07/25
52-Week
13.30 +32.56%
on 04/10/25
29.40 -40.03%
on 11/08/24
-11.37 (-39.21%)
since 11/07/24

Most Recent Stories

More News
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery...

ELVN : 17.63 (-3.66%)
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and...

ELVN : 17.63 (-3.66%)
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer rates are climbing across the U.S., with stark disparities from state to state. Recent CDC data...

ONCY : 1.0200 (+0.99%)
INAB : 1.5500 (-6.63%)
ONC.TO : 1.42 (+2.16%)
TNGX : 7.87 (-1.75%)
MBIO : 1.2200 (-3.17%)
ELVN : 17.63 (-3.66%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 1.0200 (+0.99%)
BGNE : 184.71 (+0.49%)
HCM : 14.95 (-3.24%)
ABBV : 219.16 (+0.05%)
ONC.TO : 1.42 (+2.16%)
ELVN : 17.63 (-3.66%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 1.0200 (+0.99%)
BGNE : 184.71 (+0.49%)
HCM : 14.95 (-3.24%)
ABBV : 219.16 (+0.05%)
ONC.TO : 1.42 (+2.16%)
ELVN : 17.63 (-3.66%)
Ex-congressional candidate and FTX executive's romantic partner indicted on campaign finance charges

A one-time congressional candidate and romantic partner of a convicted FTX executive has been arrested on campaign finance charges

ELVN : 17.63 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO....

See More

Key Turning Points

3rd Resistance Point 20.02
2nd Resistance Point 19.21
1st Resistance Point 18.42
Last Price 17.63
1st Support Level 16.82
2nd Support Level 16.01
3rd Support Level 15.22

See More

52-Week High 29.40
Fibonacci 61.8% 23.25
Fibonacci 50% 21.35
Fibonacci 38.2% 19.45
Last Price 17.63
52-Week Low 13.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar